Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Stage IV Prostate Cancer
Conditions
Brief summary
This phase Ib trial studies the dose and schedule of 177Lu-PSMA-617 and pembrolizumab in treating persons with castration-resistant prostate cancer that has spread to other places in the body. 177Lu-PSMA-617 carries a radioactive component which attached to the prostate specific membrane antigen (PSMA) receptor found on tumor cells. Its radiation component destroys the tumor cell. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving 177Lu-PSMA-617 and pembrolizumab may work better at treating prostate cancer.
Detailed description
PRIMARY OBJECTIVES: 1. To determine the recommended phase 2 dose and schedule of lutetium Lu 177-PSMA-617 (177Lu-PSMA-617) in combination with pembrolizumab in participants with metastatic castration-resistant prostate carcinoma (mCRPC). (Part A) 2. To determine the objective response rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. (Part B (Dose Expansion)) SECONDARY OBJECTIVES: 1. To characterize the safety profile of the combination. 2. To determine the median duration of response by RECIST 1.1 criteria. 3. To determine the proportion of participants who experience \>= 50% decline from baseline in serum prostate-specific antigen (PSA). 4. To determine the median PSA progression-free survival. 5. To determine the median time to symptomatic skeletal related event. 6. To determine the 6 month radiographic progression-free survival rate and median radiographic progression-free survival. 7. To determine the median overall survival. CORRELATIVE OBJECTIVES: 1. To assess the lesion-specific response rate by baseline PSMA avidity on gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) positron emission tomography (PET). 2. To quantify the change from baseline in T cell repertoire, circulating T cell subsets, tumor infiltrating lymphocytes, and tumor programmed death-ligand 1 (PD-L1) expression by immunohistochemistry after one priming dose of Lu-PSMA radioligand therapy (RLT). 3. To explore the relationship between timing of the 177Lu-PSMA-617 priming dose with initiation of pembrolizumab with respect to immunologic, safety, and efficacy outcomes. 4. To descriptively characterize the patterns of uptake on 68Ga-PSMA-11 PET at the time of disease progression. 5. To explore relationship between tumor genomic profile with clinical outcomes including response rate and progression-free survival. 6. To explore the relationship between tumor dosimetry with objective response. OUTLINE: Participants are assigned sequentially to 1 of 3 treatment schedules. DOSING SCHEDULE 1: Participants receive lutetium Lu 177-PSMA-617 intravenously (IV) over 20-30 minutes on day 1 before beginning pembrolizumab IV over 30 minutes on day 1 in cycle 2 DOSING SCHEDULE 2: Participants receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes concurrently with pembrolizumab IV over 30 minutes on day 1. DOSING SCHEDULE 3: Starting day -21, participants receive pembrolizumab IV over 30 minutes. Participants then receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes on day 1. In all dosing schedules, treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Participants who achieve stable disease (SD) or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab. After completion of study treatment, participants are followed up at 30 days after treatment has been discontinued.
Interventions
Given IV
BIOLOGICALPembrolizumab
Given IV
Sponsors
Prostate Cancer Foundation
National Cancer Institute (NCI)
University of California, San Francisco
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The subject is able and willing to comply with study procedures and provide signed and dated informed consent * Histologically confirmed prostate adenocarcinoma. De novo small cell neuroendocrine prostate cancer will not be allowed due to putative lower PSMA expression in this tumor subtype. Treatment-emergent small cell neuroendocrine prostate cancer detected in metastatic tumor biopsy is not an exclusion * A minimum of three PSMA-avid lesions on baseline 68Ga-PSMA-11 PET, with positive lesions defined as those with maximum standardized uptake value (SUVmax) values greater than liver. * Progressive metastatic castration-resistant prostate cancer by Prostate Cancer Working Group (PCWG)3 criteria at the time of study entry * Castrate level of serum testosterone at study entry (\< 50 ng/dL). Participants without prior bilateral orchiectomy are required to remain on luteinizing hormone-releasing hormone (LHRH) analogue treatment for duration of study * Prior progression on at least one second generation androgen signaling inhibitor including abiraterone, apalutamide, darolutamide, and/or enzalutamide * Absolute neutrophil count \> 1.5 x 10\^9/L * Hemoglobin \> 9.0 g/dL * Platelet count \> 100,000/microliter * Serum creatinine =\< 1.5 x upper limit of normal (ULN) or estimated glomerular filtration rate (GFR) \> 50 ml/min by Cockcroft-Gault or 24 hour urine collection * Total bilirubin =\< 1.5 x ULN. In participants with known or suspected Gilbert's disease, direct bilirubin =\< ULN * Aspartate aminotransferase and alanine aminotransferase =\< 2.5 x ULN (\<= 5 x ULN in participants with liver metastases) * No other systemic anti-cancer therapies administered other than LHRH analogue within 14 days, or 5 half-lives, whichever is shorter, prior to initiation of study treatment. Adverse events related to prior anti-cancer treatment other than LHRH analog treatment must have recovered to Grade \<= 1 with the exception of any grade alopecia and grade \<= 2 neuropathy. * Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Participants must use appropriate methods of contraception during study treatment and for at least 60 days after last study treatment * Participants who are sexually active should consider their female partner to be of childbearing potential if she has experienced menarche and is not postmenopausal (defined as amenorrhea \> 24 consecutive months) or has not undergone successful surgical sterilization. Even women who use contraceptive hormones (oral, implanted, or injected), an intrauterine device, or barrier methods (diaphragms, condoms, spermicide) should be considered to be of childbearing potential * Participants who have undergone vasectomy themselves should also be considered to be of childbearing potential * Acceptable methods of contraception include continuous total abstinence, or double-barrier method of birth control (e.g. condoms used with spermicide, or condoms used with oral contraceptives). Periodic abstinence and withdrawal are not acceptable methods of contraception * Participants must provide consent to comply to recommended radioprotection precautions during study * Participants willing to undergo tumor biopsy and have at least one lesion safely accessible to tumor biopsy. Bone or soft tissue lesion is allowed * Measurable disease by RECIST 1.1 criteria
Exclusion criteria
* Untreated brain metastases at study entry. Participants with previously treated brain metastases are eligible provided the following criteria are all met: * Last treatment was \> 28 days prior to cycle 1 day 1 (C1D1) * No evidence of new/progressive brain metastases is observed on magnetic resonance imaging (MRI) obtained during screening window * Patient is clinically stable without requirement of steroid treatment for at least 14 days prior to first dose of study treatment * Receipt of prior PSMA-directed treatment (e.g. radiotherapy, immunotherapy, or antibody-drug conjugate) * Prior enrollment on clinical study investigating Lu-PSMA-based radioligand therapy * Prior treatment with radium-223 or other radioisotope for the treatment of prostate cancer * Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (=\< 2 weeks of radiotherapy) to non-central nervous system (CNS) disease * Receipt of prior pembrolizumab or another immune checkpoint inhibitor (e.g. nivolumab, ipilimumab) * Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment * Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent * Receipt of taxane chemotherapy applied in the castration-resistant setting. Prior receipt of taxane chemotherapy in the hormone-sensitive setting is allowed * Grade \> 2 peripheral neuropathy at the time of study entry * Has severe hypersensitivity (\>= grade 3) to pembrolizumab and/or any of its excipients * Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) or treatment with drugs (e.g. neomercazole, carbimazole, etc.) that function to decrease the generation of thyroid hormone by a hyperfunctioning thyroid gland (e.g. in Graves? disease) is not considered a form of systemic treatment of an autoimmune disease * Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy at a prednisone equivalent dose of \> 10 mg daily or other form of immunosuppressive therapy within 7 days prior to first dose of study drug * Has a history of (non-infectious) ≥ grade 2 pneumonitis/interstitial lung disease that required steroids within past 2 years or has current ≥ grade 1 pneumonitis/interstitial lung disease at the time of study enrollment.. * Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines is allowed. * Participants who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent * Has clinically significant cardiovascular disease including, but not limited to: * Uncontrolled or any New York Heart Association class 3 or 4 congestive heart failure * Uncontrolled angina, history of myocardial infarction, unstable angina or stroke within 6 months before study entry * Clinically significant arrhythmias not controlled by medication. Chronic rate controlled or paroxysmal atrial fibrillation/flutter is not an exclusion to study participation * Prior external beam radiation involving \>= 25% of bone marrow or within 14 days of start of protocol therapy * Major surgery within 28 days of study treatment \*Note: If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment. * Has an active infection requiring systemic therapy * Has a known history of human immunodeficiency virus (HIV) (screening not required) * Has a known history of hepatitis B (defined as hepatitis B surface antigen \[HBsAg\] reactive) or known active hepatitis C virus (HCV) (defined as HCV ribonucleic acid \[RNA\] \[qualitative\] is detected) infection (screening not required) * Has a known history of active Bacillus tuberculosis (TB) * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial * Any condition that, in the opinion of the principal investigator, would impair the patient's ability to comply with study procedures * History of bleeding diathesis and not currently on anti-coagulation therapy that cannot be safely discontinued for the tumor biopsy procedure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Reported Dose Limiting Toxicities (DLT) (Part A Only) | Up to 1 year | The Recommended Phase 2 Dosing Schedule (RP2DS) (Schedule 1: a single priming dose of 177Lu-PSMA-617 (7·4 giga-becquerel (GBq) \[200 millicurie (mCi)\] given 28 days before pembrolizumab; Schedule 2: a single priming dose of 177Lu-PSMA-617 given concomitant with pembrolizumab; or Schedule 3: a single priming dose of 177Lu-PSMA-617 given 21 days after the start of maintenance pembrolizumab (200 mg every 3 weeks)) will be determined from the safety data as classified by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 for dose-limiting toxicities, aggregate safety data and feasibility of administration. The number of dose-limiting toxicities reported by participants in Part A used to determine the RP2DS for participants enrolling under Part B will be reported by arm. |
| Objective Response Rate (ORR) (Part B Only) | Up to 2 years | The ORR for participants in Part B is defined as the percentage of participants in Part B who obtained a confirmed diagnosis of complete response (CR) or partial response (PR), using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for the evaluation of radiographic CTs or MRIs performed during the course of the study to assess response. The ORR will be reported with a 95% confidence interval. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Prostate-specific Antigen (PSA) Response Rate (PSA50) | Up to 3 years | The percentage of all for all participants who received at least one dose of protocol therapy (i.e., one dose of pembrolizumab or 177Lu-PSMA-617) and who also achieved a greater than 50% decline from the time of the baseline PSA value obtained on cycle 1 day 1 (C1D1) at any point in the treatment course will be reported along with the 95% confidence interval. |
| Radiographic Progression-Free Survival Rate (rPFS) at 6 Months | Up to 6 months | rPFS is defined as the percentage all for all participants who received at least one dose of protocol therapy (i.e., one dose of pembrolizumab or 177Lu-PSMA-617) and who are still alive and progression-free per RECIST v1.1 and PCWG3 criteria at 6 months. |
| Number of Participants With Treatment-related Adverse Events | Up to 2 years | The number of participants who reported adverse events defined by NCI CTCAE version 5.0 and attributed by the investigator to having been possibly, probably, or definitely related to study treatment will be reported. |
| Median Overall Survival (OS) | Up to 3 years | Median overall survival for all participants who received at least one dose of protocol therapy (i.e., one dose of pembrolizumab or 177Lu-PSMA-617) is defined as the number of months from the first date of therapy until date of death from any cause. The median number of months and 95% confidence interval will be estimated using the Kaplan-Meier method. |
| Median Time to Symptomatic Skeletal Related Event (SSRE) | Up to 3 years | Symptomatic skeletal related event is defined as the first occurrence of one or more of the following: symptomatic fracture, surgery or radiation to bone, or spinal cord compression. The median time in months to symptomatic skeletal related event for all participants who received at least one dose of protocol therapy (i.e., one dose of pembrolizumab or 177Lu-PSMA-617) will be reported with the 95% confidence interval. |
| Median PSA Progression-free Survival | Up to 3 years | PSA progression-free survival for all participants who received at least one dose of protocol therapy (i.e., one dose of pembrolizumab or 177Lu-PSMA-617) will be defined using Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria as the duration in months from date of first treatment to date the participant first meets the criteria for PSA progression for clinical progression, death, or study completion, whichever occurs first. The median duration and 95% confidence interval will be reported. |
| Median Duration of Response | Up to 3 years | The median duration of response in months for all participants who received at least one dose of protocol therapy (i.e., one dose of pembrolizumab or 177Lu-PSMA-617) and who also demonstrated a confirmed response of complete response (CR) or partial response (PR) per RECIST criteria from the time of first response until confirmed disease progression, death or study completion will be reported. |
Countries
United States
Participant flow
Pre-assignment details
In Part A, three dosing schedules of priming lutetium-177 (¹⁷⁷Lu)-PSMA-617 (vipivotide tetraxetan) were assessed. Dose expansion in phase 1b (Part B) was subsequently evaluated using the recommended phase 2 dosing schedule.
Participants by arm
| Arm | Count |
|---|---|
| Part A: Dosing Schedule 1 (Lutetium Lu 177-PSMA-617, Pembrolizumab) Participants receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes on day 1. Beginning in cycle 2, participants receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Participants who achieve stable disease (SD) or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab. | 6 |
| Part A: Dosing Schedule 2 (Lutetium Lu 177-PSMA-617, Pembrolizumab) Participants receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes and pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Participants who achieve SD or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab. | 6 |
| Part A: Dosing Schedule 3 (Lutetium Lu 177-PSMA-617, Pembrolizumab) Starting day -21, participants receive pembrolizumab IV over 30 minutes. Participants also receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Participants who achieve SD or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab. | 6 |
| Part B: Recommended Phase 2 Dosing Schedule (RP2DS) (Lutetium Lu 177-PSMA-617, Pembrolizumab) Participants will receive the RP2DS determined in Part A. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Participants who achieve SD or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab. | 25 |
| Total | 43 |
Baseline characteristics
| Characteristic | Part A: Dosing Schedule 2 (Lutetium Lu 177-PSMA-617, Pembrolizumab) | Part A: Dosing Schedule 3 (Lutetium Lu 177-PSMA-617, Pembrolizumab) | Part A: Dosing Schedule 1 (Lutetium Lu 177-PSMA-617, Pembrolizumab) | Part B: Recommended Phase 2 Dosing Schedule (RP2DS) (Lutetium Lu 177-PSMA-617, Pembrolizumab) | Total |
|---|---|---|---|---|---|
| Age, Customized 50-59 years old | 1 Participants | 1 Participants | 1 Participants | 2 Participants | 5 Participants |
| Age, Customized 60-69 years old | 2 Participants | 3 Participants | 4 Participants | 4 Participants | 13 Participants |
| Age, Customized 70-79 years old | 1 Participants | 2 Participants | 1 Participants | 12 Participants | 16 Participants |
| Age, Customized 80-89 years old | 2 Participants | 0 Participants | 0 Participants | 6 Participants | 8 Participants |
| Age, Customized 90-99 years old | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 6 Participants | 6 Participants | 6 Participants | 25 Participants | 43 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 2 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 1 Participants | 1 Participants | 2 Participants | 5 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) White | 5 Participants | 5 Participants | 5 Participants | 19 Participants | 34 Participants |
| Region of Enrollment United States | 6 participants | 6 participants | 6 participants | 25 participants | 43 participants |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 6 Participants | 6 Participants | 6 Participants | 25 Participants | 43 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 4 / 6 | 3 / 6 | 4 / 6 | 5 / 25 |
| other Total, other adverse events | 6 / 6 | 6 / 6 | 6 / 6 | 24 / 25 |
| serious Total, serious adverse events | 0 / 6 | 2 / 6 | 1 / 6 | 5 / 25 |
Outcome results
Primary
Number of Reported Dose Limiting Toxicities (DLT) (Part A Only)
The Recommended Phase 2 Dosing Schedule (RP2DS) (Schedule 1: a single priming dose of 177Lu-PSMA-617 (7·4 giga-becquerel (GBq) \[200 millicurie (mCi)\] given 28 days before pembrolizumab; Schedule 2: a single priming dose of 177Lu-PSMA-617 given concomitant with pembrolizumab; or Schedule 3: a single priming dose of 177Lu-PSMA-617 given 21 days after the start of maintenance pembrolizumab (200 mg every 3 weeks)) will be determined from the safety data as classified by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 for dose-limiting toxicities, aggregate safety data and feasibility of administration. The number of dose-limiting toxicities reported by participants in Part A used to determine the RP2DS for participants enrolling under Part B will be reported by arm.
Time frame: Up to 1 year
Population: Schedule 1, a single priming dose of 177Lu-PSMA-617 given 28 days before pembrolizumab was determined to be the RP2DS for participants enrolled under Part B
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part A: Dosing Schedule 1 (Lutetium Lu 177-PSMA-617, Pembrolizumab) | Number of Reported Dose Limiting Toxicities (DLT) (Part A Only) | 0 dose-limiting toxicities |
| Part A: Dosing Schedule 2 (Lutetium Lu 177-PSMA-617, Pembrolizumab) | Number of Reported Dose Limiting Toxicities (DLT) (Part A Only) | 1 dose-limiting toxicities |
| Part A: Dosing Schedule 3 (Lutetium Lu 177-PSMA-617, Pembrolizumab) | Number of Reported Dose Limiting Toxicities (DLT) (Part A Only) | 1 dose-limiting toxicities |
Primary
Objective Response Rate (ORR) (Part B Only)
The ORR for participants in Part B is defined as the percentage of participants in Part B who obtained a confirmed diagnosis of complete response (CR) or partial response (PR), using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for the evaluation of radiographic CTs or MRIs performed during the course of the study to assess response. The ORR will be reported with a 95% confidence interval.
Time frame: Up to 2 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part A: Dosing Schedule 1 (Lutetium Lu 177-PSMA-617, Pembrolizumab) | Objective Response Rate (ORR) (Part B Only) | 56 percentage of participants |
Secondary
Median Duration of Response
The median duration of response in months for all participants who received at least one dose of protocol therapy (i.e., one dose of pembrolizumab or 177Lu-PSMA-617) and who also demonstrated a confirmed response of complete response (CR) or partial response (PR) per RECIST criteria from the time of first response until confirmed disease progression, death or study completion will be reported.
Time frame: Up to 3 years
Population: Per the pre-specified statistical analysis plan outlined in the study protocol, additional efficacy endpoints other than ORR including median duration of response was planned to be analyzed in the overall study cohort (n = 43). There was no pre-specified plan to analyze efficacy outcomes by study schedule (schedule 1, 2, 3). Post-hoc determination of efficacy outcomes for schedules 1,2, 3 analyzed separately is precluded by the limited sample size on schedules 2 and 3 (n = 6 each).
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part A: Dosing Schedule 1 (Lutetium Lu 177-PSMA-617, Pembrolizumab) | Median Duration of Response | 8.1 months |
Secondary
Median Overall Survival (OS)
Median overall survival for all participants who received at least one dose of protocol therapy (i.e., one dose of pembrolizumab or 177Lu-PSMA-617) is defined as the number of months from the first date of therapy until date of death from any cause. The median number of months and 95% confidence interval will be estimated using the Kaplan-Meier method.
Time frame: Up to 3 years
Population: Per the pre-specified statistical analysis plan outlined in the study protocol, additional efficacy endpoints other than ORR including Median Overall Survival (OS) was planned to be analyzed in overall study cohort (n = 43). There was no pre-specified plan to analyze efficacy outcomes by study schedule (schedule 1, 2, 3). Post-hoc determination of efficacy outcomes for schedules 1,2, 3 analyzed separately is precluded by the limited sample size on schedules 2 and 3 (n = 6 each).
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part A: Dosing Schedule 1 (Lutetium Lu 177-PSMA-617, Pembrolizumab) | Median Overall Survival (OS) | 28.2 months |
Secondary
Median PSA Progression-free Survival
PSA progression-free survival for all participants who received at least one dose of protocol therapy (i.e., one dose of pembrolizumab or 177Lu-PSMA-617) will be defined using Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria as the duration in months from date of first treatment to date the participant first meets the criteria for PSA progression for clinical progression, death, or study completion, whichever occurs first. The median duration and 95% confidence interval will be reported.
Time frame: Up to 3 years
Population: Per the pre-specified statistical analysis plan outlined in the study protocol, additional efficacy endpoints other than ORR including Median PSA progression-free survival was planned to be analyzed in overall study cohort (n = 43). There was no pre-specified plan to analyze efficacy outcomes by study schedule (schedule 1, 2, 3). Post-hoc determination of efficacy outcomes for schedules 1,2, 3 analyzed separately is precluded by the limited sample size on schedules 2 and 3 (n = 6 each).
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part A: Dosing Schedule 1 (Lutetium Lu 177-PSMA-617, Pembrolizumab) | Median PSA Progression-free Survival | 6.9 months |
Secondary
Median Time to Symptomatic Skeletal Related Event (SSRE)
Symptomatic skeletal related event is defined as the first occurrence of one or more of the following: symptomatic fracture, surgery or radiation to bone, or spinal cord compression. The median time in months to symptomatic skeletal related event for all participants who received at least one dose of protocol therapy (i.e., one dose of pembrolizumab or 177Lu-PSMA-617) will be reported with the 95% confidence interval.
Time frame: Up to 3 years
Population: Per the pre-specified statistical analysis plan outlined in the study protocol, additional efficacy endpoints other than ORR including median time to SSRE was planned to be analyzed in overall study cohort (n = 43). There was no pre-specified plan to analyze efficacy outcomes by study schedule (schedule 1, 2, 3). Post-hoc determination of efficacy outcomes for schedules 1, 2, 3 analyzed separately is precluded by the limited sample size on schedules 2 and 3 (n = 6 each).
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part A: Dosing Schedule 1 (Lutetium Lu 177-PSMA-617, Pembrolizumab) | Median Time to Symptomatic Skeletal Related Event (SSRE) | 24.7 months |
Secondary
Number of Participants With Treatment-related Adverse Events
The number of participants who reported adverse events defined by NCI CTCAE version 5.0 and attributed by the investigator to having been possibly, probably, or definitely related to study treatment will be reported.
Time frame: Up to 2 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part A: Dosing Schedule 1 (Lutetium Lu 177-PSMA-617, Pembrolizumab) | Number of Participants With Treatment-related Adverse Events | 0 participants |
| Part A: Dosing Schedule 2 (Lutetium Lu 177-PSMA-617, Pembrolizumab) | Number of Participants With Treatment-related Adverse Events | 1 participants |
| Part A: Dosing Schedule 3 (Lutetium Lu 177-PSMA-617, Pembrolizumab) | Number of Participants With Treatment-related Adverse Events | 2 participants |
| Part B: Recommended Phase 2 Dosing Schedule (RP2DS) (Lutetium Lu 177-PSMA-617, Pembrolizumab) | Number of Participants With Treatment-related Adverse Events | 9 participants |
Secondary
Prostate-specific Antigen (PSA) Response Rate (PSA50)
The percentage of all for all participants who received at least one dose of protocol therapy (i.e., one dose of pembrolizumab or 177Lu-PSMA-617) and who also achieved a greater than 50% decline from the time of the baseline PSA value obtained on cycle 1 day 1 (C1D1) at any point in the treatment course will be reported along with the 95% confidence interval.
Time frame: Up to 3 years
Population: Per the pre-specified statistical analysis plan outlined in the study protocol, additional efficacy endpoints other than ORR including PSA50 was planned to be analyzed in the overall study cohort (n = 43). There was no pre-specified plan to analyze efficacy outcomes by study schedule (schedule 1, 2, 3). Post-hoc determination of efficacy outcomes for schedules 1,2, 3 analyzed separately is precluded by the limited sample size on schedules 2 and 3 (n = 6 each).
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Part A: Dosing Schedule 1 (Lutetium Lu 177-PSMA-617, Pembrolizumab) | Prostate-specific Antigen (PSA) Response Rate (PSA50) | 44 percentage of participants |
Secondary
Radiographic Progression-Free Survival Rate (rPFS) at 6 Months
rPFS is defined as the percentage all for all participants who received at least one dose of protocol therapy (i.e., one dose of pembrolizumab or 177Lu-PSMA-617) and who are still alive and progression-free per RECIST v1.1 and PCWG3 criteria at 6 months.
Time frame: Up to 6 months
Population: Per the pre-specified statistical analysis plan outlined in the study protocol, additional efficacy endpoints other than ORR including rPFS at 6 months was planned to be analyzed in the overall study cohort (n = 43). There was no pre-specified plan to analyze efficacy outcomes by study schedule (schedule 1, 2, 3). Post-hoc determination of efficacy outcomes for schedules 1,2, 3 analyzed separately is precluded by the limited sample size on schedules 2 and 3 (n = 6 each).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part A: Dosing Schedule 1 (Lutetium Lu 177-PSMA-617, Pembrolizumab) | Radiographic Progression-Free Survival Rate (rPFS) at 6 Months | 51 percentage of participants |